On the recordSeptember 25, 2019
It seems like from the data we have looked at and from the testimony we've heard today, the pharmaceutical companies are not earning anywhere close to that necessary return on investment.
Source
congress.govEditor's note · Context
Johnson discusses pharmaceutical companies' returns compared to European markets.
Share & report
More from Royal Johnson
Apr 30, 2024
You get a lot of people bonded out on a $20 bond, for something where if you did that in Mitchell, you'd be doing six months in jail.
Nov 1, 2023
In your July hearing, witness after witness talked about the abysmal track record of IHS. It is really unacceptable.
Nov 29, 2023
Access to the capital necessary for ESOP conversion has been a major barrier to establishing more employee-owned companies.
Jul 23, 2024
H.R. 8955 would require the IHS to solicit the history of an applicant from every state medical board where the applicant is licensed.
Other voices in this conversation
